Physician profile
Tuan V Ta
NPI 1114103124
$3,191.05
in general payments reported to CMS, 2019-2025
10 companies · $746 in 2025
The $746 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $32.20 · 2021: $558 · 2022: $287 · 2023: $740 · 2024: $527 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,158.19 | 2019-2025 | Biktarvy, Yeztugo |
| Shionogi INC | $910.93 | 2020-2025 | Fetroja |
| Merck Sharp & Dohme LLC | $630.30 | 2021-2025 | Zerbaxa, Dificid, Recarbrio |
| Ferring Pharmaceuticals INC. | $144.97 | 2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $109.70 | 2023 | |
| Viiv Healthcare Company | $85.88 | 2021-2024 | Cabenuva, Dovato |
| Paratek Pharmaceuticals, INC. | $83.00 | 2021 | |
| Janssen Products, LP | $29.99 | 2021 | |
| Allergan, INC. | $21.19 | 2019 | |
| Melinta Therapeutics, LLC | $16.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tuan Ta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.